GC Biopharma Corrects Typo in Curevo Stake Sale Disclosure, No Financial Impact
This amended disclosure primarily corrects a simple typo in the original major announcement filed on May 27, 2026 regarding the sale of Curevo shares.
The original disclosure incorrectly stated the payment receipt date as July 9, 2027, which has now been corrected to July 9, 2026.
No changes have been made to the core transaction terms including the sale amount and conditions, and the already received Upfront Payment and future milestone schedule remain unchanged.
[AI Summary]This amendment is merely a clerical correction with no alteration to transaction size or terms, thus having zero impact on shareholder value. While the underlying sale remains positive, this filing itself is an administrative event with no investment implications.
KOSPI Filing Information
[Correction of Description] Report on Major Matters (Decision on Transfer of Stocks and Investment Securities of Other Corporations)